Global Markets Direct’s, ''Ovarian Cancer Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, co...
|
$ 2500
|
|
|
Epithelial Ovarian Cancer – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Epithelial Ovarian Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the
|
$ 2000
|
|
|
Ovarian Cancer Global Clinical Trials Review, H2, 2012
Summary
GlobalData''s clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H2, 2012" provides data on the Ovarian Cancer clinical trial scenario. This report provides elemen
|
$ 2500
|
|
|
Ovarian Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic developme
|
$ 2500
|
|
|
Metastatic Ovarian Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Metastatic Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the
|
$ 2000
|
|
|
TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Glo...
|
$ 1500
|
|
|
Incident and prevalent cases of ovarian cancer will increase across the seven major markets between 2011 and 2021. In all markets, these increases will be primarily due to the underlying population age structure. This trend is driven by the increa...
|
$ 3800
|
|
|
Report SummaryClinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in OncologyGBI Research, the leading business intelligence pro...
|
$ 3500
|
|
|
GlobalData’s pharmaceuticals report, “Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Avastin sales forecasts for US, EU5 and Japan. In additio
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Gemzar sales forecasts for US, EU5 and Japan. In addition,
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Farletuzumab sales forecasts for US, EU5 and Ja
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Votrient sales forecasts for US, EU5 and Japan. In addi
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Hycamtin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Hycamtin sales forecasts for US, EU5 and Japan. In addi
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Opaxio sales forecasts for the US. In addition, it covers d
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug...
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, “Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020” provides Vargatef sales forecasts for the US and EU5. In addition,
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Karenitecin sales estimates for the US, EU and Jap
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclical sales estimates for the US and EU5. In additio
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclitaxel sales forecasts for the US, EU and Japan
|
$ 2000
|
|
|
GlobalData’s pharmaceuticals report, "Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Cisplatin sales forecasts for the US, EU and Japan. I
|
$ 2000
|
|
|